Clearmind Medicine: Japan patent application published
The published application includes 3-MMC treatment claims and combinations with PEA, while Clearmind says it cannot assure that a patent will issue.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Clearmind Medicine Inc. (CMND) announced publication in Japan of a patent application covering 3-MMC compositions and methods to prevent, treat or reduce dyskinesia symptoms, including combinations with N-acylethanolamines, notably PEA. The applications are part of Clearmind’s ongoing collaboration with NeuroThera Labs Inc.; the company says PEA technology is integrated into its psychedelic-derived therapeutic programs. Clearmind reports that its intellectual property portfolio consists of 19 patent families, including 32 granted patents. The company cautioned that it cannot assure a patent will issue from the pending application.
Key Figures
Key Terms
dyskinesia medical
3-Methylmethcathinone (3-MMC) medical
N-acylethanolamines technical
Palmitoylethanolamide (PEA) medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Clearmind Medicine’s Japanese patent application cover?
Has Clearmind’s Japanese patent application resulted in a granted patent?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: October 2026
Commission file number: 001-41557
CLEARMIND MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Attached hereto and incorporated herein is the Registrant’s press release issued on October 8, 2026, titled “Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder.”
| 1 |
EXHIBIT INDEX
| Exhibit No. | ||
| 99.1 | Press release titled: “Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder” |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Clearmind Medicine, Inc. | ||
| (Registrant) | ||
| Date: October 8, 2026 | By: | /s/ Adi Zuloff-Shani |
| Name: | Adi Zuloff-Shani | |
| Title: | Chief Executive Officer | |
| 3 |
Exhibit 99.1
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)
Vancouver, Canada, Oct. XX, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (“3-MMC”) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions comprising 3-MMC. The application also includes claims for combinations of 3-MMC with N-acylethanolamines, notably Palmitoylethanolamide (“PEA”, a compound with established anti-inflammatory and neuroprotective properties.
These patent applications are part of the ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage biotech company. Through this partnership with NeuroThera, PEA technology is integrated into Clearmind’s psychedelic-derived therapeutic programs. “
Our strategy is to build robust intellectual property protection around our novel therapeutic platforms and their broad potential across neurological disorders,” said Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind. “The publication of the patent application in Japan and strengthens our global IP position for our 3-MMC-based approach to dyskinesia, including its combination with PEA.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its strategy is to build robust intellectual property protection around its novel therapeutic platforms and their broad potential across neurological disorders and strengthening our global IP position. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.